Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017.
Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017.
复制标题
DOI：
10.1111/add.13910
复制
发表时间：
2017-12
期刊：
影响因子：
--
通讯作者：
Burris S
中科院分区：
文献类型：
--
作者：
Klieger SB;Gutman A;Allen L;Pacula RL;Ibrahim JK;Burris S
1)描述为研究用途而创建的开源法律的数据集，这些数据集涵盖了美国各州医用大麻法律的关键条款。这些数据记录了州立法者如何监管一种药物，根据联邦法律，这种药物仍然是一种附表I非法药物，没有合法的医疗用途。2)证明各州在管理患者访问、产品安全和药房实践的规则中存在的差异。两名法律的研究人员收集并编码了2017年2月1日生效的关于大麻患者，产品安全和药房的州法律，创建了三个经验法律的数据集。我们使用汇总表来确定每个州的医用大麻法中规定的具体法定条款的变化，因为它存在于2017年2月1日。我们将这些法律的各个方面与传统的联邦管理医学的方法进行了比较。完整的数据集、编码手册和协议可通过处方药滥用政策系统（http：//www.pdaps.org/; http：//www.webcitation.org/6qv5CZNaZ）查阅。28个州（包括哥伦比亚特区）已经批准了医用大麻。27个州指定了符合条件的疾病，各州的情况各不相同。所有的州都保护病人的隐私，只有14个州保护病人不受歧视。18个州在任何销售之前都有强制性的产品安全测试。虽然大多数国家都有包装/标签法规，但各州有各种具体要求。大多数规范药房，在具体规定方面有很大差异，如允许的产品供应来源，每个州的药房数量以及限制接近各种类型的地点。美国的联邦大麻禁令导致了一系列监管策略的拼凑，这些策略与联邦政府通常采取的方法并不一致，其有效性仍然未知。
1) To describe open source legal datasets, created for research use, that capture the key provisions of U.S. state medical marijuana laws. The data document how state lawmakers have regulated a medicine that remains, under federal law, a Schedule I illegal drug with no legitimate medical use. 2) To demonstrate the variability that exists across states in rules governing patient access, product safety, and dispensary practice. Two legal researchers collected and coded state laws governing marijuana patients, product safety, and dispensaries in effect on February 1, 2017, creating three empirical legal datasets. We used summary tables to identify the variation in specific statutory provisions specified in each state’s medical marijuana law as it existed on February 1, 2017. We compared aspects of these laws to the traditional Federal approach to regulating medicine. Full datasets, codebooks and protocols are available through the Prescription Drug Abuse Policy System (http://www.pdaps.org/; http://www.webcitation.org/6qv5CZNaZ). Twenty-eight states (including the District of Columbia) have authorized medical marijuana. Twenty-seven specify qualifying diseases, which differ across states. All states protect patient privacy; only 14 protect patients against discrimination. Eighteen states have mandatory product safety testing before any sale. While the majority have package/label regulations, states have a wide range of specific requirements. Most regulate dispensaries, with considerable variation in specific provisions such as permitted product supply sources, number of dispensaries per state and restricting proximity to various types of location. The federal ban in the USA on marijuana has resulted in a patchwork of regulatory strategies that are not uniformly consistent with the approach usually taken by the Federal government and whose effectiveness remains unknown.
登录
查看更多内容
影响因子：
6
作者：
Kilmer, Beau;Pacula, Rosalie Liccardo
通讯作者：
Pacula, Rosalie Liccardo
影响因子：
39
作者：
Bachhuber, Marcus A.;Saloner, Brendan;Cunningham, Chinazo O.;Barry, Colleen L.
通讯作者：
Barry, Colleen L.
影响因子：
3.7
作者：
Morris RG;TenEyck M;Barnes JC;Kovandzic TV
通讯作者：
Kovandzic TV
影响因子：
5.5
作者：
Naimi, Timothy S.;Blanchette, Jason;Xuan, Ziming
通讯作者：
Xuan, Ziming
影响因子：
2.2
作者：
Anderson, D. Mark;Hansen, Benjamin;Rees, Daniel I.
通讯作者：
Rees, Daniel I.